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Understanding the determinants of the 
complex interplay between cost-effectiveness 
and equitable impact in maternal and child 
mortality reduction
Background One of the most unexpected outcomes arising from the 
efforts towards maternal and child mortality reduction is that all too 
often the objective success has been coupled with increased ineq-
uity in the population. The aim of this study is to analyze the deter-
minants of the complex interplay between cost-effectiveness and eq-
uity and suggest strategies that will promote an impact on mortality 
that reduce population child health inequities.
Methods We developed a conceptual framework that exposes the na-
ture of the links between the five key determinants that need to be 
taken into account when planning equitable impact. These determi-
nants are: (i) efficiency of intervention scale-up (requires knowledge 
of differential increase in cost of intervention scale-up by equity strata 
in the population); (ii) effectiveness of intervention (requires under-
standing of differential effectiveness of interventions by equity strata 
in the population); (iii) the impact on mortality (requires knowledge 
of differential mortality levels by equity strata, and understanding the 
differences in cause composition of overall mortality in different eq-
uity strata); (iv) cost-effectiveness (compares the initial cost and the 
resulting impact on mortality); (v) equity structure of the population. 
The framework is presented visually as a four-quadrant graph.
Results We use the proposed framework to demonstrate why the 
relationship between cost-effectiveness and equitable impact of an 
intervention cannot be intuitively predicted or easily planned. The 
relationships between the five determinants are complex, often non-
linear, context-specific and intervention-specific. We demonstrate 
that there will be instances when an equity-promoting approach, ie, 
trying to reach for the poorest and excluded in the population with 
health interventions, will also be the most cost-effective approach. 
However, there will be cases in which this will be entirely unfeasible, 
and where equity-neutral or even inequity-promoting approaches 
may be substantially more cost-effective. In those cases, investments 
into health system development among the poorest that would in-
crease the quality and reduce the cost of intervention delivery would 
be required before intervention scale-up is planned.
Conclusions The relationships between the most important deter-
minants of cost-effectiveness and equitable impact of health inter-
ventions used to reduce maternal and child mortality are highly com-
plex, and the effect on equity cannot be predicted intuitively, or by 
using simple linear models.
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In recent years, enormous efforts have been made to esti-
mate the global burden of maternal and child mortality and 
identify the main causes, study the role of risk factors, as-
sess the effectiveness of available interventions, and to track 
the coverage of those interventions in low and middle-in-
come countries [1-10]. However, this large body of evi-
dence has not been followed by the development of suffi-
ciently simple and accurate tools and approaches that 
effectively translate the evidence and information into 
health policy decisions where this is most needed – at the 
national and sub-national level in low-resource settings. In 
the absence of evidence-based planning, it is not surpris-
ing that unexpected outcomes can arise from efforts to-
wards maternal and child mortality reduction. One of the 
most perplexing outcomes is that all too often the objective 
success in mortality reduction has been coupled with an 
increased health inequity in the population [11].
To understand the roots of this problem, we should appre-
ciate that policy makers at the national and sub-national 
level have limited resources for scaling up cost-effective 
health interventions in their populations. When planning 
the “best buys” for committing their resources in maternal 
and child health, they are faced with a very complex task. 
They need to choose between at least several dozen inter-
ventions that target neonates, infants, children and moth-
ers, most of which have been proven to be cost-effective in 
many contexts [4,5,8,9]. They soon realize that it would 
take more than a simple calculation to decide on the most 
rational way to invest in health intervention scale up. De-
pending on the local and national context, the interplay 
between many important factors will affect both cost-effec-
tiveness and the impact on equity for their chosen inter-
vention scale-up programs. Neglect (or improper under-
standing) of these complexities can lead to decisions which 
result in maternal and child mortality reduction not being 
achieved in the most cost-effective way, or being associated 
with increases in health inequity within communities. The 
present set of tools does not sufficiently capture the full ar-
ray of factors [12].
The aim of this study is to analyze the determinants of the 
complex interplay between cost-effectiveness and equity in 
maternal and child mortality reduction and suggest strate-
gies that promote an impact on mortality that will reduce 
population child health inequities. To achieve this aim, we 
develop a transparent framework based on several key ep-
idemiological concepts that can be used to support nation-
al-level decision making in health intervention prioritiza-
tion. Using this framework, we try to expose the complex 
interplay among factors that influence both cost-effective-
ness and equity in child and maternal mortality reduction 
and identify the key information needs for planning of eq-
uitable and cost-effective programs of health intervention 
scale-up.
METHODS
The cost of intervention scale-up in 
different equity strata
The first important determinant to consider is the cost of in-
tervention scale-up in different equity strata. In our framework, 
we will divide any population of interest into 5 equity stra-
ta (quintiles), each comprising 20% of the population, 
where Q1 denotes the wealthiest quintile and Q5 the poor-
est. The cost of achieving complete coverage with any health 
intervention will clearly differ between the wealthiest (Q1) 
and the poorest (Q5) quintile, but there is remarkably little 
information available on the determinants of these costs in 
each quintile and the actual differences in cost of implemen-
tation. It is also clear that these differences between strata 
will be intervention-specific and also context-specific, rath-
er than following any “standard”, predictable pattern. This 
means that, for some interventions, the costs may not in-
crease dramatically (from the wealthiest to the poorest quin-
tile) with increasing coverage. In fact, wherever the salary 
of health professionals is the main component of the cost, 
then it is possible to envisage circumstances in which, for 
some interventions, it may be even cheaper to cover the 
poorest quintile (eg, when there is a well-developed net-
work of village health workers who can administer cheap 
antibiotic treatment) than the wealthiest quintile (where this 
depends on skilled medical doctors who have access to both 
cheap and more expensive antibiotics). However, there will 
also be many examples where complete intervention cover-
age will be more readily achieved among the wealthy Q1 
than in the poorest Q5, where it may be almost impossible 
or even unfeasible to achieve.
Figure 1 summarizes this relationship. The horizontal axis 
represents the increasing cost required for scaling up of an 
intervention, while the vertical axis measures the complete-
ness of coverage in each equity quintile (ranging from 0% 
to 20% of the total population). Recently, substantial efforts 
have been made to track the coverage of interventions spe-
cifically by equity strata in many low and middle-income 
countries. This work has indicated that this is an important 
component that will be need to be included in planning 
the equitable delivery of interventions [13-15]. However, 
we still need information on the actual cost components of 
intervention scale-up and how these differ across wealth 
quintiles in varying contexts and for each intervention. In 
reality, this cost cannot be expressed as a fixed amount in 
US$ per person that is characteristic of each delivered in-
tervention, nor does it increase linearly as the achieved 
population coverage increases (Figure 1). The cost of in-
tervention scale-up includes more than just the market cost 
of an intervention (such as vaccine or a drug), because the 
successful delivery also requires everything else that is re-
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quired to reach the targeted recipients, such as costs of 
health worker salaries, transport and storage, improved ac-
cess and expanded outreach.
Those additional costs may be relatively small if the aim 
was to cover the most accessible 20% or 40% of mothers 
and children. In these circumstances the relationship be-
tween cost and achieved coverage may indeed be approxi-
mately linear. However, additional costs of intervention de-
livery will start increasing in complex and nonlinear 
patterns when the coverage of the most deprived children 
and mothers is attempted, because many obstacles need to 
be overcome to reach them. Because of these additional 
costs, all too often we observe that the most accessible 
mothers and children are being covered with ever more in-
terventions, while the marginalized are missing out on all 
of them. This approach would still be expected to reduce 
maternal and child mortality, but the progress would be 
very slow and inequitable. This is because most child and 
maternal deaths occur among the most inaccessible parts 
of the population and only a minor part of the mortality 
burden is being targeted with interventions. The progress 
that is being achieved benefits only those who are acces-
sible, thus increasing inequity. Reducing the additional 
costs of intervention delivery when targeting the poor 
would involve challenges that are related to both supply 
and demand for the prioritized interventions.
One examples of this relationship between cost and 
achieved intervention scale-up by equity quintiles (Q1-Q5) 
is shown in Figure 1. This graph summarizes the efficiency 
of intervention delivery. In this hypothetical example, it is 
apparent that for the same intervention it is much cheaper, 
and therefore more efficient, to achieve full coverage in the 
most wealthy 20% of the population (Q1) than in the poor-
est quintile (Q5). In fact, in this example the difference in 
cost is so large that it poses a question whether the poten-
tial for mortality reduction in the poorest quintile (Q5) jus-
tifies such an inefficient delivery of a life-saving interven-
tion at such a high cost? Sometimes, even when the equity 
argument is being respected, it may still be entirely unfea-
sible to attempt to reach the poorest Q5, because the infra-
structure that would allow this in a cost-effective way sim-
ply does not exist. In such cases, investing in health system 
development may need to precede investing in interven-
tion coverage. We will move through the rest of the frame-
work to explore this further, because the answers will rare-
ly be intuitive.
The effectiveness of an intervention  
in different equity strata
The second determinant of cost-effectiveness and equity to 
consider is the effectiveness of an intervention in different eq-
uity strata. The effectiveness of an intervention, or its “po-
tential impact fraction”, indicates which proportion of the 
current mortality burden that is targeted by an intervention 
would be averted among those who receive the interven-
tion, in comparison to those that do not receive it. In the-
ory, the effectiveness of an intervention in relation to a spe-
cific cause of death – such as a specific antibiotic treatment 
against childhood pneumonia – should be relatively simi-
lar in all settings. This is because it should primarily be de-
termined by the biology of disease and the interplay be-
tween the disease and the intervention. However, the 
experience from the field tells us that the effectiveness of 
the same intervention may differ substantially between Q1 
and Q5. Some of the reasons may be, in the above example, 
that there is different spectrum of pathogens among the 
very poor (and less well nourished) (Q5), and /or higher 
levels of antibiotic resistance, and/ or later presentation 
with more severe symptoms because of barriers in access 
to care or differences in care-seeking behaviour, all of 
which reduces the effectiveness of antibiotic treatment 
against pneumonia in comparison to Q1 children. In ad-
dition, and perhaps even more importantly, the quality of 
intervention delivery will not be the same in all socio-eco-
nomic strata. Incomplete or inadequate delivery will be 
more likely among the poorest (Q5), which will decrease 
the effectiveness of the intervention against the same cause 
of death. Taking the example of pneumococcal and Hib 
vaccine against pneumonia, this may be because of more 
likely interruption of the cold chain when trying to reach 
the poorest, lower level of health workers' education and 
skills which may lead more often to inadequate adminis-
tration of vaccines, and lower health awareness among the 
parents of the children leading to lower levels of full atten-
dance for all immunization appointments.
Figure 1 The relationship between cost of the intervention 
scale-up and achieved intervention coverage, which determines 
the efficiency of intervention delivery, presented for each of the 
five equity strata in the population (Q1 – the wealthiest 
quintile; Q5 – the poorest quintile).
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We tried to capture this complex relationship between the 
achieved coverage by equity quintiles and the effectiveness 
in mortality reduction in Figure 2. In order to expose the 
continuum of relationships and effects that the important 
determinants in this framework have on mortality reduc-
tion and equity, the vertical axis is taken from Figure 1. It 
again shows the achieved coverage by each equity quintile, 
which can range from 0 to 20%. The horizontal axis shows 
the effectiveness of the intervention of interest in terms of 
reduction in mortality in each equity stratum (expressed as 
a proportion of the total mortality in that stratum) that 
could be achieved for a given level of coverage shown on 
the vertical axis. The value on the horizontal axis where the 
coverage in Q1 becomes complete (in this case, between 
50% and 60%) shows the maximum potential for the in-
tervention to reduce mortality against a specific cause un-
der ideal conditions. For example, if the cause of death of 
interest is pneumonia; if 50%-60% of pneumonia deaths 
in this setting are caused by Pneumococcus; and if pneumo-
coccal vaccine is nearly 100% effective in preventing pneu-
mococcal pneumonia deaths, then this is the maximum 
potential effectiveness of pneumococcal vaccine under ide-
al conditions. However, the adverse factors explained 
above (interruption of the cold chain, inadequate admin-
istration by health workers, failure to comply with full vac-
cination schedule by the parents) may act to reduce its ef-
fectiveness to only 20%-30% among the poorest section of 
the population in Q5, even when the full coverage is 
achieved (Figure 2). Presently, there is remarkably little 
understanding or evidence about the nature and scale of 
differences in effectiveness of health interventions in differ-
ent equity strata, although this is one of the most important 
determinants of overall cost-effectiveness and equitable im-
pact.
The size and composition of the mortality 
burden in different equity strata
The third important determinant to consider is the absolute 
size of the mortality burden in different equity strata and its 
composition. The relationship between the burden of mor-
tality and equity strata is rather predictable: the absolute 
number of deaths will always be much greater in the poor-
est (Q5) than in the wealthiest quintile (Q1), given that the 
quintiles are of the same size by definition (ie, 20% of pop-
ulation), and that mortality rates are greater among the 
poor. However, the graph that captures this relationship 
(Figure 3) may still look very differently, depending of the 
level of inequity in the population. The lines representing 
the five equity strata in this graph may be relatively close 
to each other such as in a situation where the burden of 
mortality is, in absolute terms, only 2 times greater in Q5 
compared to Q1. However, these lines could also be far 
apart such as when the burden of mortality is 10 times 
greater in Q5 than in Q1. In a sense, Figure 3 is a visual-
ization of the level of inequity in a society when expressed 
as bearing the burden of mortality. A substantial effort has 
been invested in recent years to understand and explore 
the differences in mortality rates between the equity strata 
in low and middle-income countries [9,14,16,17].
There is another factor that adds complexity to the relation-
ship between intervention effectiveness and number of 
deaths averted by equity strata, as shown in Figure 3. The 
breakdown of the overall number of deaths by cause of 
death may differ quite substantially between equity quin-
tiles. For example, causes of deaths among the wealthiest 
children will be dominated by congenital abnormalities, 
preterm birth complications and accidents – ie, the prob-
lems that even well-functioning health system still can’t 
easily tackle effectively. However, the poorest children will 
mainly be expected to die from infectious causes, such as 
pneumonia, diarrhea, malaria and neonatal sepsis. As an 
example, the proportional contribution of pneumonia to 
all child deaths observed in a developing country would 
typically be around 10% in the wealthiest quintile of chil-
dren rising to up to 40% among the poorest children [18]. 
This is why the “potential impact fraction” of an interven-
tion that only targets pneumonia in reduction of the over-
all child mortality burden could be much larger in the 
poorest (Q5) than in the wealthiest quintile (Q1) despite 
lower quality of delivery in Q5 settings acting to reduce the 
intervention effectiveness.
Figure 2 The relationship between achieved intervention 
coverage and potential impact fraction, which determines the 
effectiveness of the intervention, presented for each of the five 
equity strata in the population (Q1 – the wealthiest quintile; Q5 
– the poorest quintile; to expose the continuum of relationships 
and effects that the important determinants in this framework 
have on mortality reduction and equity, the vertical axis is taken 
from Figure 1, while the horizontal axis measures the effective-
ness in different equity strata).
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The graph presented in Figure 3 therefore exposes the po-
tential impact of intervention delivery to reduce the burden 
of mortality in absolute terms. In the hypothetical case 
shown in Figure 3, it is apparent that for an intervention 
that targets eg, infectious causes, it is usually more effective 
to achieve full coverage in the poorest 20% of the popula-
tion, regardless of the reduced effectiveness because of 
poorer quality of delivery. However, for interventions that 
target causes of deaths that are more prominent among the 
wealthiest, such as eg, congenital abnormalities, these re-
lationships would be inverse. Similarly, if a cause of death 
is equally important in all 5 strata, then the effectiveness of 
an intervention would usually be greater among the 
wealthy, because the lower quality of delivery and increased 
barriers to access and care-seeking would reduce it among 
the poor.
The cost-effectiveness of investing in 
different equity strata
The fourth determinant to consider is the one that usually 
drives policy decisions: the number of deaths averted per cost 
of intervention scale-up in different equity strata. Health inves-
tors usually like to know how many deaths could be avert-
ed with a fixed level of investment. The more deaths avert-
ed per fixed investment, the more cost-effective the scale 
up. Therefore, Figure 4 exposes the cost-effectiveness of 
many competing investment options.
Figure 4 is drawn using the “cost” from Figure 1 as a hor-
izontal axis, and “the number of deaths averted” from Fig-
ure 3 as the vertical axis. When the cost is low and the 
number of averted deaths high (ie, the bottom-right corner 
of Figure 4), the intervention scale-up is highly cost-effec-
tive. When the cost is high and the number of averted 
deaths low (ie, the top-left corner of Figure 4), the inter-
vention scale-up is not cost-effective. In Figure 4, the hy-
pothetical program that implemented intervention “A” 
proved to be more cost-effective than the program that im-
plemented intervention “B”. However, the cost-effective-
ness of mortality reduction does not necessarily mean that 
it will also be “equitable”, as these are two separate dimen-
sions. Deaths can be reduced in a highly cost-effective way 
when investments are targeting the wealthiest quintiles, 
just as when they are targeting the poorest. In the former 
case, the mortality will be reduced, but the inequity will be 
increased. In the latter, both mortality and inequity will be 
reduced. We argue that this should be the goal whenever 
possible, and that a simple check using this framework can 
help highlight these important issues and enable decision-
making that includes this goal. Scaling up health interven-
tions in Q3 will be “equity-neutral”, scaling up in Q4 and 
Q5 will always be “equity-promoting”, while scaling up in 
Q1 and Q2 will be “inequity-promoting”; all three ap-
proaches, however, will result in reduction of mortality 
burden, and in some cases this reduction may even be more 
cost-effective when interventions are scaled in Q1 and/or 
Q2, rather than in Q4 an/or Q5.
Determinants of cost-effectiveness and equitable impact in maternal and child mortality reduction
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Figure 3 The relationship between potential impact fraction and 
number of deaths averted, which determines the potential 
impact of the intervention in mortality reduction, presented for 
each of the five equity strata in the population (Q1 – the 
wealthiest quintile; Q5 – the poorest quintile; to expose the 
continuum of relationships and effects that the important 
determinants in this framework have on mortality reduction 
and equity, the horizontal axis is taken from Figure 2, while the 
vertical axis measures the number of deaths that could 
potentially be averted in different equity strata).
IMPACT
GRAPH
Figure 4 The relationship between the cost of intervention 
scale-up and number of deaths averted, which determines the 
cost-effectiveness of the intervention in mortality reduction, 
presented for each of the five equity strata in the population 
(Q1 – the wealthiest quintile; Q5 – the poorest quintile).
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The complex interplay among factors that 
influence equity and cost-effectiveness of 
mortality reduction
If we bring together the previous four graphs into a single 
decision-making framework, as shown in Figure 5, it be-
comes clear that the relationships between the four deter-
minants (efficiency, effectiveness, impact on mortality and 
cost-effectiveness) and the impact on equity will not nec-
essarily be intuitive in any setting. The final outcome will 
be governed by a series of complex and typically nonlinear 
relationships between the determinants above. Anything 
that increases the efficiency of delivery (see arrow in the 
top left quadrant, Figure 5), the quality of delivery (see ar-
row in the top right quadrant, Figure 5), and acts upon the 
greater mortality burden (see arrow in the bottom right 
quadrant, Figure 5) will be more cost-effective (see arrows 
in the bottom left quadrant, Figure 5), and vice versa. In-
creased efficiency and quality of delivery will tend to make 
scaling up among the wealthier groups more cost-effective, 
while the increased size of the burden will tend to make 
scaling up among the poorer groups more cost-effective 
(Figure 5).
To further illustrate the nature of this complexity, Figure 5 
offers an illustrative example: a fixed sum of money (shown 
on the “cost” axis) is available to ensure delivery of an en-
tirely new intervention to children in a country. Local pol-
icy makers have a choice: if they assume that children in 
Q1 would find ways to get this intervention anyway, while 
those in Q5 are arguably too hard to reach, they could in-
vest the available funds to cover as many children in Q2, 
Q3 or Q4 as possible. The difference is that covering Q2 
would increase inequity, while covering Q4 would promote 
equity and Q3 would be equity-neutral. If similar cost-ef-
fectiveness between the three approaches could be demon-
strated (in the bottom left quadrant of the proposed frame-
work), then the equity-promoting approach (covering Q4) 
should be preferred. In this example, implementing the in-
tervention to the children in Q3 is more cost-effective than 
the other two approaches (Figure 5), but the difference is 
not substantial and covering Q4 could be considered in-
stead.
In the remainder of this paper, we will present and discuss 
a hypothetical case related to planning of the delivery of an 
intervention to different equity strata in the population and 
assessing its cost-effectiveness at different levels of invest-
ment.
RESULTS
We will consider a hypothetical case of framework imple-
mentation: planning of the delivery of a new intervention, 
such as vaccine, improved sanitation, or maternal educa-
tion program, to different social strata in the population 
and assessing its cost-effectiveness. The upper left quadrant 
graph in Figure 6 shows how the level of investment trans-
lates to intervention coverage in different equity quintiles 
in the population of interest (Q1 being the wealthiest and 
Q5 the poorest). Clearly, in the population of interest an 
Figure 5 A hypothetical case 
of planning the delivery of a 
new intervention to different 
equity strata in the popula-
tion (Q2 vs Q3 vs Q4) with a 
fixed budget and assessing its 
cost-effectiveness under 
equity-neutral (Q3), 
equity-promoting (Q4) or 
inequitable (Q2) strategy.
Chopra et al.
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investment of US$ 50 million will ensure nearly complete 
coverage of all 20% children in Q1 quintile, while complete 
coverage can be achieved with US$ 100 million in Q2. US$ 
150 million will cover about 7 out of 10 children in Q3, 
while US$ 200 million will cover two in three children in 
Q4. Reaching children in Q5 will be extremely difficult and 
expensive, and US$ 250 million will only cover about one 
third of the children in this quintile (Figure 6).
The upper right quadrant graph takes into account that the 
effectiveness of the same intervention will vary in different 
quintiles. This is because the quality of delivery usually de-
creases in the poorest equity strata, making the implemen-
tation in Q1-Q3 more effective than in Q4-Q5 (Figure 6).
The lower right quadrant graph takes into account that the 
burden of child deaths is not evenly distributed among the 
five quintiles and it quantifies the number of deaths avert-
ed. It is apparent that removing 50% of the mortality bur-
den in Q1 or Q2 removes similar number of deaths (in ab-
solute terms) as preventing 15% of deaths in Q5 (see 
Figure 6).
Finally, the lower left quadrant graph brings the number 
averted deaths back to the relationship with the initial in-
vestment in US$. This allows us to compare many different 
scenarios and make informed predictions of cost-effective-
ness of each scenario relative to alternative ones – all of 
which would be impossible to predict intuitively. Thanks 
to graphs in Figure 6, we can now conclude that an invest-
ment of US$ 50 million in coverage of children in Q1 will 
be more cost-effective than any of the other four scenarios, 
with investing US$ 250 million in covering children in Q5 
being the least cost-effective. Still, an investment of US$ 
150 million in Q5 (denoted as Q5′, follow the parallel dot-
ted lines in Figure 6) would be substantially more cost-
effective than an investment of US$ 200 million in Q4 or 
250 million in Q5. This means that it is, in fact, more cost-
effective to invest $ 150 million into the coverage of chil-
dren in the poorest quintile (Q5′) than it would be to invest 
$ 250 million into the coverage of children in Q5.
DISCUSSION
The interplay between investments to increase intervention 
coverage and the “returns” in terms of the number of deaths 
averted is extremely complex and sometimes counter-in-
tuitive. It is intervention-specific, context-specific, and it 
depends on several variables that show both linear and 
nonlinear inter-relationships. All of this should be taken 
into account when planning investment policies and choos-
ing between the many cost-effective interventions at the 
national and sub-national level. The lines in the “efficien-
cy”, “effectiveness” and “impact” graphs (Figure 5 and Fig-
ure 6) necessarily determine the resulting line in the “cost-
effectiveness” graph. Any increase in efficiency and quality 
of intervention delivery, effectiveness of intervention, or 
burden of disease within any quintile will improve cost-
effectiveness. Looking at Figure 5 and Figure 6, shows that 
any rotation of the lines in the “efficiency”, “effectiveness” 
Figure 6 Six hypothetical 
investment cases of different 
amounts of funding for 
scale-up of the same interven-
tion in 5 different equity strata, 
and with different level of 
investment into the poorest 
quintile (Q5).
Determinants of cost-effectiveness and equitable impact in maternal and child mortality reduction
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and “impact” graphs in the clock-wise direction will lead to 
rotation of the corresponding line in the “cost-effectiveness” 
graph in the anti-clockwise direction, which is desirable.
Figures 5 and Figure 6 also expose some unexpected and 
counter-intuitive properties of this framework. First, when 
lines anywhere in the graph are located counter-clockwise 
from the line determined with an equation x = y, then the 
cost-effectiveness will decrease with increasing investment 
in the same population stratum. This means that smaller 
investments in the same quintiles may prove to be more 
cost-effective than larger investments. However, if it is pos-
sible to change the slope of the lines through improving 
contexts, then a scenario may be envisaged in which in-
creasing investments in a population quintile also become 
increasingly cost-effective. This is particularly important for 
the poorest quintile, as shown in example in Figure 6. The 
scenario presented in both Figure 5 and Figure 6 has also 
shown that in some contexts the most equitable strategy 
(ie, investing in the poorest quintiles) is not necessarily the 
most cost-effective. In this case, the decision-making pro-
cess becomes really difficult, as it cannot be based on any 
rational framework, but it rather needs to include value 
choices. When faced with such an interplay of the key de-
terminants in their particular context, policy makers need 
to decide whether the majority of the society would value 
improved equity or cost-effective mortality burden reduc-
tion (ie, more deaths averted per money invested, irrespec-
tive of the increasing inequity) as the more important goal.
Given the level of general interest in tools that could trans-
late accumulated evidence and information into health pol-
icy at the national level, and also in improving equity with-
in low and middle-income countries, there is remarkably 
little evidence on the differential cost of intervention scale-
up, effectiveness of intervention, or the composition of 
mortality burden by equity strata to support even the most 
basic analysis. With recent progress in assembling informa-
tion relevant for international child health policy [1-10], 
we believe that we will soon begin to have sufficient infor-
mation to develop a model that could allow early compar-
ative analysis, such as the one described above, at the na-
tional level in several representative countries. This model 
should enable the development of guidelines for prioritiz-
ing of interventions in different contexts to maximize the 
reduction in maternal and child mortality burden relative 
to the funding available, while taking into account the re-
sulting impact on equity.
This model should not be considered in isolation from the 
other worthy and commendable efforts, all of which have 
“burden of disease/cost effectiveness analysis” as their es-
sential component, such as those promoted by the Disease 
Control Priorities Project (DCPP) [19]. For example, the 
Marginal Budgeting for Bottlenecks (MBB) tool was devel-
oped by UNICEF and The World Bank [20], WHO-
CHOICE (Choosing Interventions that are Cost-Effective) 
was developed by the World Health Organization [21], and 
Lives Saved Tool (LiST) developed by Johns Hopkins Uni-
versity scientists and the Futures Institute [22]. The DCPP 
authors correctly note that factors other than cost-effective-
ness influence priority setting in the real world, so the avail-
able evidence has to be considered in the context of local 
realities [12,19]. Both MBB and WHO-CHOICE provide 
appropriate contextualization tools. However, the LiST 
software goes further than other existing tools in several 
dimensions [12]. LiST contains an expansive evidence base 
of context-specific intervention effectiveness, generated by 
researchers from the WHO/UNICEF's Child Health Epide-
miology Reference Group (CHERG) [23]. It enables esti-
mation of intervention impact on child mortality at nation-
al, regional, and global levels [24,25]. Further important 
advantages of LiST include its validation in both African 
and South Asian contexts [26], an ability to perform very 
specific comparisons between alternative investment strat-
egies over a specified time frame in terms of child survival 
outcomes [24,25], and its attempt to apply an equity lens 
[27]. However, due to the gap in information on the key 
determinants of the interplay between cost-effectiveness 
and equitable impact in maternal and child mortality re-
duction, none of the present versions of the available tools 
allow planning of an equitable strategy to reduce maternal 
and child mortality.
CONCLUSION
In order to assess cost-effectiveness at the national and local 
level, policy makers would need to know: (i) what is the 
differential cost of intervention delivery to achieve full cov-
erage in Q1-Q5?; (ii) what is the difference in effectiveness 
of this new intervention in Q1-Q5?; (iii) what is the differ-
ence in mortality burden between Q1-Q5? The interplay 
among those key determinants needs to be understood, and 
relative trade-offs need to be quantified before investment 
decisions can be made. However, in most contexts and for 
most available interventions there is simply no information 
on differential cost of scale-up, differential effectiveness and 
differential mortality burden by equity strata.
We hereby propose a framework that exposes the most im-
portant determinants of cost-effectiveness and equitable 
impact in maternal and child mortality reduction and their 
interplay. One of the values of this framework is in suggest-
ing how to make interventions delivered to the poorest in 
the population (Q5) more cost-effective, which is primar-
ily by increasing the efficiency and the quality of interven-
tion delivery, while improving access and promoting care-
seeking behaviour and infrastructure to support delivery 
mechanisms to Q5. The framework also exposes large gaps 
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in information required to understand the interplay be-
tween the key determinants – above all, differential cost of 
intervention delivery by equity strata; differential effective-
ness of intervention by equity strata; and differential size 
and cause composition of mortality burden by equity stra-
ta. Finally, the proposed framework should enable model-
ling of the “thresholds of cost-effectiveness” for the poorest 
in the population, by starting the analysis from the bottom-
left quadrant (“cost-effectiveness graph”) with setting the 
desired level of cost-effectiveness and, given the burden of 
mortality, finding the values of effectiveness and cost of 
scale up that would be required to make the implementa-
tion cost-effective while improving equity in the popula-
tion.
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